NASDAQ:CMND Clearmind Medicine (CMND) Stock Price, News & Analysis $1.04 +0.03 (+2.97%) As of 09:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Clearmind Medicine Stock (NASDAQ:CMND) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Clearmind Medicine alerts:Sign Up Key Stats Today's Range$1.01▼$1.0150-Day Range$0.87▼$1.1652-Week Range$0.80▼$2.18Volume4,625 shsAverage Volume435,174 shsMarket Capitalization$4.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada. Read More Clearmind Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreCMND MarketRank™: Clearmind Medicine scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Clearmind Medicine. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearmind Medicine is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearmind Medicine is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearmind Medicine has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Clearmind Medicine's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.46% of the float of Clearmind Medicine has been sold short.Short Interest Ratio / Days to CoverClearmind Medicine has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearmind Medicine has recently decreased by 9.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearmind Medicine does not currently pay a dividend.Dividend GrowthClearmind Medicine does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.46% of the float of Clearmind Medicine has been sold short.Short Interest Ratio / Days to CoverClearmind Medicine has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearmind Medicine has recently decreased by 9.08%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Clearmind Medicine to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Clearmind Medicine insiders have not sold or bought any company stock.Percentage Held by Institutions96.05% of the stock of Clearmind Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Clearmind Medicine's insider trading history. Receive CMND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearmind Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMND Stock News HeadlinesClearmind Medicine Inc. Announces Publication of International Patent Application for Combination Therapy Targeting Metabolic Syndrome and ObesityAugust 7, 2025 | quiverquant.comQClearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood SugarAugust 7, 2025 | globenewswire.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.September 4 at 2:00 AM | Porter & Company (Ad)Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical CenterAugust 5, 2025 | globenewswire.comClearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver DiseaseJuly 30, 2025 | globenewswire.comClearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use DisorderJuly 23, 2025 | globenewswire.comClearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant EnrolledJuly 15, 2025 | globenewswire.comClearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant EnrolledJuly 15, 2025 | globenewswire.comSee More Headlines CMND Stock Analysis - Frequently Asked Questions How have CMND shares performed this year? Clearmind Medicine's stock was trading at $1.38 at the beginning of the year. Since then, CMND stock has decreased by 24.6% and is now trading at $1.04. How were Clearmind Medicine's earnings last quarter? Clearmind Medicine Inc. (NASDAQ:CMND) posted its earnings results on Thursday, June, 12th. The company reported ($0.16) earnings per share (EPS) for the quarter. When did Clearmind Medicine's stock split? Clearmind Medicine shares reverse split on Tuesday, November 28th 2023.The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Clearmind Medicine IPO? Clearmind Medicine (CMND) raised $9 million in an initial public offering on Tuesday, November 15th 2022. The company issued 1,300,000 shares at $6.00-$8.00 per share. Aegis Capital Corp. served as the underwriter for the IPO. Who are Clearmind Medicine's major shareholders? Top institutional investors of Clearmind Medicine include AdvisorShares Investments LLC (4.82%). How do I buy shares of Clearmind Medicine? Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Clearmind Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clearmind Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), AppLovin (APP) and e.l.f. Beauty (ELF). Company Calendar Last Earnings6/12/2025Today9/04/2025Next Earnings (Estimated)9/15/2025Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMND CIK1892500 Webwww.clearmindmedicine.com Phone604-260-1566FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-164.79% Return on Assets-71.12% Debt Debt-to-Equity RatioN/A Current Ratio1.74 Quick Ratio1.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book1.38Miscellaneous Outstanding Shares4,270,000Free FloatN/AMarket Cap$4.31 million OptionableNot Optionable Beta0.97 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:CMND) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
